FOXP3+ regulatory T-cells are abundant in vulvar Paget's disease and are associated with recurrence
- PMID: 21075432
- DOI: 10.1016/j.ygyno.2010.10.019
FOXP3+ regulatory T-cells are abundant in vulvar Paget's disease and are associated with recurrence
Abstract
Objective: To characterize clinical features of vulvar Paget's disease, and examine the quantity of immunosuppressive regulatory T-cells in vulvar Paget's tissue.
Methods: Vulvar Paget's cases from 1992 to 2007 from two institutions were identified by pathology database search. Regulatory T-cells were identified with FOXP3 immunohistochemistry and quantified at the dermal-epidermal junction using image analysis software. Thirteen non-neoplastic inflammatory cases were stained for comparison.
Results: Cases included 33 women treated for primary vulvar Paget's, and 7 referred at recurrence. Of the 24 primary cases with greater than 5 months follow-up, recurrence was documented in 12/24(50%). Eight women (20%) recurred multiple times, but no recurrences were invasive. Significantly more patients with positive margins developed recurrent disease (82% vs 23%, p=0.01). Secondary neoplasms occurred in 10/40(25%). FOXP3+ cells at the dermal-epidermal junction were quantified in 29 primary and 13 recurrent tissue samples. FOXP3+ cells were absent in surrounding normal vulvar skin. FOXP3+ cells averaged 66/HPF in primary vulvar Paget's and 66/HPF in recurrent Paget's, compared to 22/HPF in non-neoplastic inflammatory cases (p=0.0003, p=0.001). Primary cases with positive surgical margins had more FOXP3+ cells than those with negative margins (85 vs 49, p=0.01). Recurrent cases with positive margins had more FOXP3+ cells than negative cases (84 vs 33, p=0.06). FOXP3 levels in primary specimens were higher in cases which recurred (78 vs 35, p=0.02).
Conclusions: Increased regulatory T-cells may be associated with more extensive cases of vulvar Paget's disease that result in positive surgical margins and are associated with recurrence of disease, suggesting immunosuppression as a key factor.
Copyright © 2010 Elsevier Inc. All rights reserved.
Similar articles
-
Comparison of Foxp3+ regulatory T cells and CD163+ macrophages in invasive and non-invasive extramammary Paget's disease.Acta Derm Venereol. 2012 Nov;92(6):625-8. doi: 10.2340/00015555-1453. Acta Derm Venereol. 2012. PMID: 22949100
-
Cytologic detection of recurrence in extramammary Paget's disease of the vulva: a report of two cases.Acta Cytol. 2010 Sep-Oct;54(5 Suppl):1007-12. Acta Cytol. 2010. PMID: 21053588
-
Recurrence of Paget's disease: total vaginal occlusion and partial occlusion of urethra.Acta Obstet Gynecol Scand. 2012 Sep;91(9):1125-6. doi: 10.1111/j.1600-0412.2012.01424.x. Epub 2012 May 22. Acta Obstet Gynecol Scand. 2012. PMID: 22525049 No abstract available.
-
Paget's disease of the vulva: prevalence of associated vulvar adenocarcinoma, invasive Paget's disease, and recurrence after surgical excision.Am J Obstet Gynecol. 1999 Jan;180(1 Pt 1):24-7. doi: 10.1016/s0002-9378(99)70143-2. Am J Obstet Gynecol. 1999. PMID: 9914572 Review.
-
Recurrent Paget's disease of the vulva in a myocutaneous flap: case report and review of the literature.Eur J Gynaecol Oncol. 2001;22(1):13-5. Eur J Gynaecol Oncol. 2001. PMID: 11321485 Review.
Cited by
-
Metastatic Extramammary Paget's Disease: Pathogenesis and Novel Therapeutic Approach.Front Oncol. 2018 Feb 16;8:38. doi: 10.3389/fonc.2018.00038. eCollection 2018. Front Oncol. 2018. PMID: 29503810 Free PMC article. Review.
-
An advanced case of extramammary Paget disease: Safe and effective treatment in an inoperable elderly patient using extensive en face electron irradiation.JAAD Case Rep. 2018 Dec 9;5(1):72-74. doi: 10.1016/j.jdcr.2018.08.010. eCollection 2019 Jan. JAAD Case Rep. 2018. PMID: 30560191 Free PMC article. No abstract available.
-
Extramammary Paget's Disease: Diagnosis, Pathogenesis, and Treatment with Focus on Recent Developments.Curr Oncol. 2021 Aug 5;28(4):2969-2986. doi: 10.3390/curroncol28040260. Curr Oncol. 2021. PMID: 34436026 Free PMC article. Review.
-
Is There a Place for Immune Checkpoint Inhibitors in Vulvar Neoplasms? A State of the Art Review.Int J Mol Sci. 2020 Dec 27;22(1):190. doi: 10.3390/ijms22010190. Int J Mol Sci. 2020. PMID: 33375467 Free PMC article. Review.
-
Number of FoxP3+ regulatory T-cells are associated with recurrence in vulvar squamous cell carcinoma.J Gynecol Oncol. 2023 Mar;34(2):e16. doi: 10.3802/jgo.2023.34.e16. Epub 2022 Dec 7. J Gynecol Oncol. 2023. PMID: 36509463 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical